pretranspl
screen
potenti
organ
donor
recipi
essenti
part
solid
organ
transplant
goal
pretranspl
infecti
diseas
screen
identifi
condit
disqualifi
either
donor
recipi
identifi
treat
activ
infect
pretranspl
defin
level
infect
risk
order
determin
strategi
prevent
posttranspl
infect
although
gener
agreement
major
infect
screen
perform
variat
center
type
screen
util
action
taken
result
pretranspl
period
ideal
time
detail
counsel
recipi
regard
food
infect
risk
well
obtain
thorough
travel
anim
environment
exposur
histori
given
event
occur
list
transplant
patient
famili
may
overwhelm
may
necessari
impart
inform
cours
sever
session
aid
reinforc
inform
updat
patient
regard
newer
risk
recommend
import
time
updat
immun
well
sinc
often
effect
administ
prior
transplant
larg
varieti
pathogen
may
transmit
transplant
guidelin
pretranspl
screen
subject
sever
recent
public
includ
consensu
confer
immunocompromis
host
societi
ich
american
societi
transplant
ast
clinic
practic
guidelin
evalu
renal
transplant
candid
astp
clinic
practic
guidelin
evalu
live
renal
transplant
donor
updat
recommend
regard
hepat
statu
donor
summar
march
crystal
citi
meet
review
chung
feng
delmonico
addit
center
diseas
control
prevent
cdc
infecti
diseas
societi
america
idsa
american
societi
blood
marrow
transplant
asbmt
publish
guidelin
prevent
infect
hematopoiet
stem
cell
transplant
recipi
cdc
publish
guidelin
prevent
hiv
transmiss
transplant
brief
discuss
differ
screen
live
deceas
donor
review
summar
current
opinion
screen
bacteri
mycobacteri
fungal
parasit
viral
infect
donor
recipi
detail
discuss
infect
correspond
posttranspl
monitor
prophylaxi
found
section
guidelin
viral
serolog
donor
recipi
close
tie
togeth
discuss
togeth
given
limit
pool
donor
becom
increasingli
import
consid
margin
candid
includ
infect
time
donat
natur
infect
sever
recipi
ill
import
consider
determin
accept
infect
donor
differ
screen
live
donor
deceas
donor
larg
base
differ
time
frame
screen
take
place
live
donor
possibl
treat
activ
infect
defer
transplant
infect
resolv
live
donor
screen
conduct
transplant
center
time
screen
transplant
variabl
especi
altruist
donor
program
requir
reflect
period
greater
month
clinic
event
occur
interim
taken
account
time
transplant
repeat
serolog
test
consid
presenc
behavior
chang
appropri
clinic
symptom
sign
particularli
febril
flulik
ill
time
initi
screen
transplant
screen
prospect
live
donor
includ
thorough
medic
histori
physic
examin
laboratori
studi
includ
serolog
test
tabl
radiograph
studi
need
medic
histori
includ
previou
infect
vaccin
travel
occup
exposur
well
assess
presenc
riski
behavior
drug
use
sexual
practic
incarcer
live
donor
screen
untreat
syphili
ppd
skin
test
perform
see
contrast
time
frame
deceas
donor
evalu
typic
hour
laboratori
associ
organ
hepat
b
surfac
antibodi
hbsab
gener
safe
organ
donat
hepat
b
core
antibodi
igg
hbcab
igg
highrisk
transmiss
liver
use
donat
use
center
intens
prophylaxi
nonhepat
organ
carri
small
risk
transmissionof
hbv
use
vaccin
recipi
prophylaxi
rpr
contraind
donat
recipi
receiv
benzathin
penicillin
antibodi
toxoplasma
contraind
donat
sulfaallerg
seroneg
heart
transplant
recipi
seroposit
donor
receiv
pyrimethamin
prophylaxi
procur
organ
opo
oper
basi
gener
inform
need
determin
donor
suitabl
short
time
frame
possibl
certain
infect
hiv
hcv
may
present
earli
stage
prior
develop
specif
antibodi
thu
consider
weight
place
donor
social
medic
histori
identifi
potenti
risk
might
reflect
serolog
test
furthermor
certain
infect
eg
donor
bacteremia
may
come
light
transplant
perform
futur
rapid
molecular
test
may
grant
opo
capabl
immedi
detect
particularli
viral
infect
hcv
hiv
evalu
detail
reveal
activ
bacteri
infect
present
live
donor
infect
respiratori
tract
urinari
tract
focal
site
thoroughli
treat
resolut
infect
document
particular
caution
must
employ
urinari
tract
infect
occur
potenti
kidney
donor
make
sure
repres
occult
upper
tract
infect
ill
occur
might
involv
bacteremia
thorough
investig
perform
make
sure
target
organ
seed
syphili
may
latent
asymptomat
requir
therapi
time
permit
howev
syphili
rare
transmit
transplant
contraind
organ
donat
recipi
treat
posttranspl
appropri
cours
benzathin
penicillin
aii
deceas
donor
may
harbor
known
unsuspect
bacteri
infect
rapidli
evalu
review
medic
record
temperatur
chart
radiographi
cultur
avail
organ
known
infect
transplant
aii
desir
obtain
blood
cultur
sinc
occult
donor
bacteremia
may
occur
addit
risk
sepsi
welldocu
case
occur
mycot
aneurysm
vascular
anastomos
recipi
due
donor
bacteremia
virul
organ
staphylococcu
aureu
pseudomona
although
recent
review
bacterem
donor
found
evid
transmiss
recipi
given
antimicrobi
therapi
mean
day
posttranspl
prudent
employ
longer
cours
therapi
eg
week
donor
known
bacterem
potenti
virul
organ
biii
gener
compel
evid
support
treat
recipi
receiv
allograft
deceas
donor
nonbacterem
local
infect
involv
transplant
organ
except
mening
ciii
organ
success
transplant
donor
bacteri
mening
evid
infecti
complic
recipi
appropri
antimicrobi
therapi
administ
donor
recipi
donor
lung
colon
case
lung
transplant
deserv
special
attent
donor
bacteri
colon
extrem
common
given
lung
contact
extern
environ
donor
bronchoscopi
cultur
perform
time
lung
transplant
allow
administr
antibiot
direct
colon
organ
thu
prevent
invas
infect
recipi
aiii
allograft
contamin
may
occur
procur
process
rubin
recommend
administr
antibiot
recipi
organ
isol
perfus
organ
transplant
medium
cite
risk
mycot
aneurysm
format
discuss
antibiot
given
least
day
gramneg
bacilli
staphylococcu
aureu
candida
speci
biii
shorter
cours
therapi
may
consid
less
virul
organ
ciii
although
one
studi
donor
left
atrial
cultur
preserv
fluid
cultur
show
correl
cultur
infect
heart
transplant
recipi
recipi
receiv
direct
antibiot
therapi
mycobacterium
tuberculosi
transmit
transplant
donor
transmiss
account
approxim
report
posttranspl
tb
case
larg
review
patient
singh
paterson
potenti
live
donor
ppd
tuberculin
skin
test
perform
posit
undergo
addit
screen
rule
activ
diseas
aii
abnorm
chest
xray
symptom
suggest
possibl
activ
diseas
sputum
afb
cultur
perform
chest
ct
help
urin
afb
cultur
often
obtain
case
ppdposit
prospect
kidney
donor
radiographi
perform
donor
pretranspl
evalu
often
provid
clue
present
past
tubercul
diseas
urinari
tract
sign
symptom
activ
diseas
chest
xray
normal
sputum
afb
cultur
lowyield
although
time
frame
evalu
deceas
donor
allow
tuberculin
skin
test
donor
activ
tuberculosi
clinic
possibl
util
aii
donor
posit
ppd
without
evid
activ
diseas
may
donat
organ
even
never
receiv
prophylaxi
donor
ppd
posit
without
prior
therapi
list
indic
isoniazid
prophylaxi
recipi
review
singh
paterson
biii
past
decis
whether
prophylax
individu
base
upon
weigh
risk
activ
tuberculosi
potenti
toxic
isoniazid
see
mycobacteri
infect
section
guidelin
howev
risk
isoniazid
hepatotox
may
high
previous
thought
especi
nonhepat
transplant
recipi
activ
invas
fungal
infect
donor
contraind
transplant
howev
endem
mycos
particular
may
present
dormant
form
transmiss
histoplasmosi
transplant
describ
case
appear
result
reactiv
past
infect
recipi
mani
individu
midwestern
usa
calcifi
hilar
splenic
granulomata
xray
may
visibl
residua
old
histoplasma
infect
radiograph
sign
tradit
consid
contraind
donat
biii
transmiss
coccidioidomycosi
lung
transplant
report
southwestern
usa
although
reactiv
coccidioidomycosi
recipi
appear
far
common
yet
uniform
recommend
donor
screen
endem
mycos
emerg
toxoplasmosi
major
concern
particularli
heart
transplant
toxoplasmaseroneg
recipi
toxoplasmaseroposit
heart
highest
risk
develop
activ
toxoplasmosi
posttranspl
toxoplasmosi
also
rare
transmit
liver
kidney
recipi
knowledg
donor
seroposit
contraind
heart
donat
allow
appropri
prophylaxi
administ
screen
donor
toxoplasma
routin
perform
noncardiac
donor
transmiss
chaga
diseas
trypanosoma
cruzi
transplant
signific
problem
endem
area
south
latin
america
recent
report
usa
routin
screen
yet
mandat
usa
prospect
donor
resid
endem
area
advis
aiii
discuss
issu
found
parasitolog
section
guidelin
follow
section
discuss
donor
recipi
screen
viral
infect
sinc
combin
donor
recipi
serolog
often
crucial
determin
risk
infect
viral
infect
mention
discuss
detail
section
guidelin
cmv
serolog
statu
donor
recipi
import
predictor
posttranspl
event
cmv
seroneg
recipi
cmv
seroposit
donor
organ
dr
highest
risk
develop
tissueinvas
cmv
recurr
cmv
ganciclovirresist
cmv
howev
drstatu
gener
consid
contraind
transplant
indic
intens
monitor
prevent
strategi
posttranspl
ai
seroposit
recipi
regardless
donor
statu
also
risk
cmv
usual
receiv
either
prophylaxi
preemptiv
monitor
mani
differ
protocol
use
full
discuss
cmv
prevent
found
anoth
section
posttranspl
lymphoprolif
diseas
ptld
fear
complic
transplant
highest
ptld
risk
ebv
seroneg
recipi
ebv
seroposit
graft
commonli
occur
pediatr
recipi
occasion
occur
adult
ptld
also
develop
seroposit
recipi
influenc
augment
immunosuppress
awar
pretranspl
serolog
target
highest
risk
group
close
monitor
ebvpcr
preemptiv
therapi
herpesvirus
clinic
import
transplant
recipi
includ
herp
simplex
viru
varicellazost
viru
vzv
human
kshv
hsv
screen
perform
center
wherea
center
administ
univers
antivir
prophylaxi
least
first
month
posttranspl
vzv
screen
recipi
extrem
import
varicella
vaccin
ideal
administ
pretranspl
seroneg
recipi
prevent
sever
primari
varicella
occur
transplant
aii
addit
knowledg
vzv
serostatu
transplant
import
manag
vzv
exposur
recent
awar
possibl
role
roseolovirus
cofactor
cmv
effect
fungal
infect
possibl
allograft
dysfunct
led
increas
interest
virus
sinc
almost
adult
seroposit
howev
donor
recipi
screen
virus
gener
recommend
whether
screen
would
help
pediatr
transplant
program
yet
unknown
agent
kaposi
sarcoma
reactiv
transplant
occasion
may
transmit
transplant
may
also
associ
ebvneg
lymphoprolif
diseas
optim
strategi
prevent
reactiv
defin
recommend
pretranspl
screen
yet
emerg
ciii
issu
surround
hbv
transplant
discuss
detail
hepat
section
guidelin
donor
screen
usual
includ
least
hbsag
hbv
core
antibodi
hbcab
use
perform
igg
igm
donor
hbsag
posit
hbcabigm
posit
indic
activ
hbv
infect
hbsag
neg
hbcabigm
posit
person
may
window
period
donor
gener
util
although
center
use
donor
intens
posttranspl
prophylaxi
isol
hbsab
posit
usual
indic
prior
vaccin
resolv
infect
gener
consid
risk
hbv
transmiss
complex
question
use
hbsag
neg
hbcabigg
posit
donor
may
repres
either
falseposit
test
isol
hbcab
posit
prior
latent
hbv
infect
latter
signific
risk
transmiss
hbv
liver
transplant
recipi
therefor
liver
often
util
dii
howev
center
success
util
liver
hbcab
posit
donor
intens
posttranspl
prophylaxi
risk
transmiss
nonhepat
recipi
appear
low
zero
risk
diminish
pretranspl
hbv
vaccin
recipi
center
restrict
use
organ
lifethreaten
situat
andor
vaccin
recipi
would
util
posttranspl
prophylaxi
hepat
b
immun
globulin
hbig
andor
lamivudin
transplant
nonimmun
recipi
bii
possibl
offer
organ
prudent
vaccin
seroneg
transplant
candid
hbv
vaccin
although
respons
vaccin
patient
endstag
organ
diseas
may
suboptim
aii
donor
hbvdna
level
provid
help
inform
design
prophylact
strategi
even
result
receiv
transplant
detail
recommend
posttranspl
prophylaxi
found
chung
et
al
hbv
section
guidelin
recipi
screen
hbv
help
posttranspl
manag
patient
undergo
liver
transplant
endstag
liver
diseas
due
hbv
varieti
posttranspl
protocol
prevent
reactiv
hbv
mani
util
hbig
nonhepat
transplant
hbsag
posit
recipi
controversi
earli
day
kidney
transplant
transplant
perform
recipi
develop
earli
fulmin
liver
diseas
greater
number
develop
longterm
chronic
liver
diseas
maintain
asymptomat
statu
mani
year
despit
evid
activ
viral
replic
period
time
hbsagposit
statu
consid
contraind
nonhepat
transplant
effect
therapi
lamivudin
avail
appear
theoret
possibl
transplant
recipi
safe
although
lamivudin
resist
may
becom
issu
ciii
adefovir
success
use
treat
lamivudineresist
hbv
hepat
c
viru
hcv
infect
frequent
chronic
hcv
major
indic
liver
transplant
although
hcv
recurr
common
posttranspl
patient
graft
surviv
significantli
wors
pretranspl
diagnos
hcv
seroposit
renal
transplant
candid
higher
risk
liver
diseas
sepsi
nonhepat
transplant
hcv
seroneg
counterpart
compar
transplant
altern
balanc
benefit
often
fall
side
transplant
role
pretranspl
viral
load
reduct
studi
strategi
manag
hcv
recipi
discuss
detail
later
section
hepat
c
posit
donor
tradit
consid
dilemma
high
risk
transmiss
hcv
transplant
organ
posit
hcvrna
indic
activ
viral
replic
associ
higher
risk
transmiss
often
inform
avail
deceas
donor
time
frame
futur
rapid
molecular
test
like
becom
avail
time
frame
need
donor
evalu
recent
crystal
citi
meet
emphas
valid
util
hcv
posit
donor
certain
circumst
increas
mortal
morbid
demonstr
transplant
liver
kidney
hcvposit
donor
vs
hcvneg
donor
hcvposit
recipi
bii
recent
year
use
hcvposit
organ
lifesav
transplant
hcvneg
recipi
also
studi
sometim
accept
result
survey
lung
transplant
program
show
program
util
hcv
seroposit
donor
mani
case
restrict
hcv
seroposit
recipi
survey
heart
transplant
program
reveal
center
use
hcv
seroposit
donor
wherea
center
util
donor
statu
candid
hcvposit
recipi
center
list
hcv
posit
candid
heart
transplant
howev
recent
seri
identifi
excess
rapidli
progress
cholestat
hepat
increas
mortal
hcv
seroneg
recipi
donor
seroposit
heart
graft
mycophenolatebas
immunosuppress
whether
specif
immunosuppress
regimen
prefer
situat
requir
studi
event
whenev
hcv
seroposit
donor
util
stringent
inform
consent
advis
hivseroposit
donor
tradit
util
serolog
usual
obtain
potenti
donor
recipi
rare
usa
posit
screen
serolog
often
falseposit
western
blot
test
obtain
confirm
posit
screen
test
either
doubt
exist
possibl
exposur
potenti
live
donor
hiv
seroneg
molecular
viral
test
obtain
posit
prior
develop
posit
antibodi
test
use
rapidli
avail
molecular
test
hiv
also
desir
deceas
donor
technolog
becom
avail
although
previous
consid
contraind
transplant
hiv
seroposit
recipi
receiv
renew
attent
mani
patient
hiv
highli
activ
antiretrovir
therapi
haart
regimen
live
longer
far
less
immunocompromis
case
endstag
organ
failur
rather
hiv
survivallimit
condit
multicent
trial
current
evalu
feasibl
transplant
individu
preliminari
result
transplant
well
toler
meticul
clinic
care
care
attent
pharmacokinet
complex
issu
involv
fulli
discuss
hiv
section
guidelin
human
tlymphotrop
viru
htlvi
endem
certain
part
world
includ
caribbean
japan
often
asymptomat
howev
infect
htlvi
progress
year
decad
htlvi
associ
myelopathytrop
spastic
paraparesi
hamtsp
adult
cell
leukemialymphoma
atl
progress
occur
seroposit
individu
endem
region
respect
htlvii
viru
serolog
difficult
distinguish
htlvi
although
associ
diseas
process
less
certain
pcr
assay
use
distinguish
htlvi
ii
necessari
htlvi
seroposit
donor
gener
util
although
use
donor
could
consid
lifethreaten
situat
particularli
older
recipi
stringent
inform
consent
ciii
although
case
atl
occur
transplant
report
none
observ
seri
japanes
htlvi
seroposit
recipi
undergo
renal
transplant
west
nile
viru
wnv
flaviviru
caus
meningoenceph
recent
appear
usa
fall
cdc
investig
transmiss
wnv
transplant
four
organ
recipi
singl
donor
report
addit
report
transmiss
blood
transfus
liver
transplant
appear
unclear
yet
magnitud
risk
transmiss
pattern
wnv
activ
chang
yearli
basi
serolog
pcr
wnv
avail
timeconsum
prudent
avoid
donor
unexplain
possibl
viral
ill
andor
unexplain
mental
statu
chang
sinc
juli
us
blood
bank
product
test
wnv
use
investig
nucleic
acid
amplif
test
nat
perform
specif
center
fall
us
health
resourc
servic
administr
hrsa
issu
guidanc
statement
regard
donor
wnv
recommend
test
prospect
live
donor
nat
test
close
time
transplant
avoid
donor
form
enceph
heighten
clinic
suspicion
part
treat
clinician
febril
ill
occur
shortli
transplant
time
current
requir
transport
sampl
center
perform
nat
test
test
deceas
donor
yet
univers
recommend
may
voluntarili
undertaken
organ
procur
organ
conjunct
laboratori
perform
nat
test
part
canada
test
donor
wnv
igm
well
nat
test
perform
sinc
earli
occurr
spread
sar
sever
acut
respiratori
syndrom
grow
concern
new
respiratori
ill
appear
due
previous
undescrib
coronaviru
affect
individu
may
requir
mechan
ventil
full
spectrum
clinic
manifest
still
determin
risk
transmiss
health
care
worker
well
household
contact
affect
individu
least
one
death
transplant
recipi
due
sar
updat
inform
sar
epidemiolog
infect
control
relat
topic
found
cdc
websit
http
wwwcdcgovncidodsar
health
canada
websit
http
wwwhcsccaenglishsar
transmiss
transplant
theoret
possibl
extent
risk
unknown
current
principl
donor
recipi
select
would
like
exclud
patient
recent
acut
ill
meet
sar
criteria
howev
consequ
remot
histori
sar
subclin
ill
unknown
screen
tool
potenti
adult
pediatr
donor
propos
evolv
univers
toronto
transplant
program
kumar
humar
u
allen
person
commun
take
account
risk
sar
transmiss
donor
hospit
well
donor
symptom
travel
contact
histori
like
guidelin
becom
formal
inform
avail
new
emerg
potenti
communic
agent
may
aris
addit
wnv
sar
may
affect
donor
accept
recipi
activ
transplant
list
would
advis
avoid
transplant
involv
individu
potenti
communic
infect
inadequ
inform
exist
provid
appropri
recommend
regard
precautionari
measur
transplant
recipi
risk
infect
relat
complic
organ
failur
patient
await
renal
transplant
may
infect
hemodialysi
periton
dialysi
access
site
cathet
complic
upperandor
lowertract
urinari
infect
candid
await
liver
transplant
risk
aspir
pneumonia
spontan
bacteri
periton
urinari
tract
infect
infect
associ
intraven
cathet
candid
await
heart
transplant
may
infect
relat
either
indwel
intraven
cathet
ventricular
assist
devic
vad
util
bridg
transplant
see
addit
heart
candid
also
risk
pneumonia
set
congest
heart
failur
debilit
vad
ventricular
assistdevic
associ
infect
treat
prior
transplant
infect
common
vad
larg
foreign
bodi
may
place
month
longer
portal
entri
frequent
abdomin
wall
exit
site
drive
line
may
exit
site
drainag
local
infect
proxim
infect
vad
pocket
bacteremia
endocard
caus
organ
includ
coagulaseneg
staphylococci
staphylococcu
aureu
aerob
gramneg
bacilli
yeast
protract
antibacteri
therapi
may
lead
candida
superinfect
infect
contraind
transplant
howev
total
remov
vad
time
transplant
combin
appropri
posttranspl
antibiot
therapi
often
cur
screen
lung
transplant
recipi
includ
assess
colon
airway
flora
care
review
previou
pulmonari
infect
cystic
fibrosi
patient
may
colon
multiresist
strain
pseudomona
andor
burkholderia
cepacia
controversi
whether
patient
colon
burkholderia
exclud
receiv
lung
transplant
molecular
type
burkholderia
isol
promis
method
may
use
defin
risk
futur
patient
ppd
tuberculin
skin
test
perform
prior
transplant
posit
skin
test
histori
activ
tuberculosi
undergo
care
addit
screen
rule
activ
diseas
see
aii
anergi
panel
help
interpret
neg
ppd
patient
endstag
organ
diseas
isoniazid
hepatotox
appear
less
problem
origin
thought
transplant
recipi
therefor
patient
histori
posit
ppd
radiograph
evid
prior
tb
prophylaxi
consid
isoniazid
prophylaxi
aii
prophylaxi
start
patient
transplant
wait
list
complet
patient
list
transplant
inde
desir
least
prophylaxi
cours
administ
prior
onset
transplant
immunosuppress
patient
clinic
histori
radiograph
andor
cultur
suggest
infect
tb
nontubercul
mycobacteria
patient
undergo
thorough
evalu
possibl
activ
diseas
may
includ
ct
scan
bronchoscopi
test
deem
clinic
necessari
mycobacteri
infect
fulli
treat
document
microbiolog
radiograph
resolut
transplant
consid
pretranspl
colon
fungal
isol
aspergillu
common
lung
transplant
recipi
particularli
cystic
fibrosi
patient
colon
prompt
rigor
evalu
exclud
activ
infect
although
posttranspl
aspergillosi
fear
complic
transplant
clinician
gener
reli
posttranspl
preemptiv
prophylact
strategi
rather
pretranspl
antifung
therapi
colon
patient
pretranspl
candid
invas
fungal
infect
rather
colon
treat
least
radiograph
clinic
microbiolog
resolut
order
minim
risk
highmort
infect
posttranspl
aiii
pretranspl
screen
endem
mycos
use
area
endem
coccidioidomycosi
pretranspl
histori
activ
diseas
andor
seroposit
may
prompt
lifelong
azol
prophylaxi
aii
pretranspl
screen
histoplasmosi
limit
valu
sinc
latent
histoplasmosi
may
present
neg
serolog
diii
instead
heighten
awar
possibl
histoplasmosi
reactiv
import
investig
posttranspl
febril
ill
patient
endem
area
patient
endem
area
travel
extend
period
time
endem
area
strongyloidiasi
includ
tropic
countri
part
southeastern
usa
risk
develop
dissemin
strongyloidiasi
transplant
although
center
screen
stool
ova
parasit
examin
expert
favor
screen
serolog
strongyloid
far
sensit
stool
exam
biii
seroposit
patient
short
cours
thiabendazol
ivermectin
indic
pretranspl
although
random
data
lack
biii
discuss
toxoplasma
serolog
import
heart
recipi
seroneg
heart
recipi
seroposit
donor
receiv
prophylaxi
aii
chaga
diseas
parasit
infect
fulli
discuss
parasit
infect
section
guidelin
activ
primari
infect
virus
cmv
ebv
hbv
time
transplant
uncommon
nonetheless
activ
viral
infect
detect
potenti
recipi
eg
cmv
would
wise
delay
transplant
infect
resolv
order
allow
develop
natur
immun
prior
transplant
immunosuppress
aiii
recommend
also
extend
candid
present
transplant
clinic
symptom
suggest
acut
communityacquir
viral
infect
chanc
exposur
hiv
pretranspl
potenti
recipi
hiv
molecular
detect
test
well
hiv
antibodi
test
hiv
antibodi
may
take
month
develop
aii
viral
screen
donor
recipi
discuss
detail
pretranspl
evalu
present
import
opportun
updat
potenti
recipi
immun
sinc
mani
vaccin
effect
administ
prior
onset
transplant
immunosuppress
aii
detail
immun
recommend
summar
later
section
guidelin
varicellaseroneg
candid
ideal
immun
varicella
prior
transplant
aii
howev
transplant
expect
immin
may
best
withhold
varicella
vaccin
live
attenu
vaccin
biii
yearli
influenza
vaccin
administ
transplant
candid
aii
vaccin
household
contact
health
care
worker
also
import
immunocompromis
patient
may
mount
optim
antibodi
respons
vaccin
aii
use
recent
licens
live
influenza
vaccin
avoid
transplant
expect
within
month
vaccin
hepat
b
vaccin
seri
ideal
administ
pretranspl
seroneg
individu
aii
especi
potenti
donor
may
found
hbsagneg
hbcabposit
clinician
advoc
acceler
cours
rather
tradit
dose
month
data
await
ciii
respons
vaccin
like
better
earli
diseas
rather
endstag
organ
diseas
occur
enhanc
potenc
formul
dialysi
patient
other
avail
bii
patient
advanc
liver
diseas
particularli
high
risk
fulmin
hepat
receiv
hepat
vaccin
aii
vaccin
like
effect
administ
earli
liver
diseas
bii
combin
hepat
b
vaccin
immunogen
data
await
transplant
candid
recipi
measlesmumpsrubella
vaccin
mmr
live
vaccin
patient
born
consid
immun
due
natur
immun
patient
born
receiv
second
dose
mmr
vaccin
recommend
receiv
second
dose
especi
highrisk
group
health
care
worker
administ
mmr
given
prerath
posttranspl
bii
pneumococc
polysaccharid
vaccin
ideal
also
administ
transplant
candid
age
receiv
within
past
year
aii
pleas
see
immun
section
pediatr
recommend
tetanusdiphtheria
toxoid
td
booster
administ
potenti
adult
recipi
td
booster
within
year
aii
prevent
strategi
infect
limit
medic
vaccin
thorough
educ
patient
famili
member
import
prevent
tool
pretranspl
class
print
materi
help
includ
inform
handwash
safeti
measur
environment
exposur
activ
avoid
food
safeti
handl
foodborn
pathogen
pet
travel
see
strategi
safe
live
follow
solid
organ
transplant
also
help
patient
gener
idea
infect
transplant
patient
suscept
prevent
strategi
use
particular
center
pretranspl
screen
donor
recipi
afford
opportun
assess
safeti
candid
organ
determin
prophylaxi
prevent
strategi
util
posttranspl
detect
fulli
treat
activ
infect
potenti
recipi
prior
transplant
updat
vaccin
statu
potenti
recipi
educ
patient
famili
prevent
measur
advanc
futur
like
includ
rapid
molecular
diagnost
test
refin
assess
risk
transmiss
pose
particular
donor
